Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, July 2001, p. 757-761, Vol. 8, No. 4
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.4.757-761.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Role of Nijmegen Breakage Syndrome Protein in
Specific T-Lymphocyte Activation Pathways
Miguel Angel
García-Pérez,1
Luis
M.
Allende,1
Alfredo
Corell,1
Estela
Paz-Artal,1
Pilar
Varela,1
Alberto
López-Goyanes,1
Francisco
García-Martin,2
Rosario
Vázquez,2
Amalia
Sotoca,1 and
Antonio
Arnaiz-Villena1,*
Department of Immunology, Hospital
Universitario 12 de Octubre, Universidad Complutense, Carretera de
Andalucia, 28041 Madrid,1 and Department
of Pediatrics, Hospital Regional Carlos Haya,
Málaga,2 Spain
Received 23 October 2000/Returned for modification 13 December
2000/Accepted 22 March 2001
 |
ABSTRACT |
Nijmegen breakage syndrome (NBS) is a genetic disorder
characterized by immunodeficiency, microcephaly, and "bird-like"
facies. NBS shares some clinical features with ataxia telangiectasia
(AT), including increased sensitivity to ionizing radiation, increased spontaneous and induced chromosome fragility, and strong predisposition to lymphoid cancers. The mutated gene that results in NBS codes for a
novel double-stranded DNA break repair protein, named nibrin. In the
present work, a Spanish NBS patient was extensively characterized at
the immunological and the molecular DNA levels. He showed low CD3+-cell numbers and an abnormal low CD4+
naive cell/CD4+ memory cell ratio, previously described in
AT patients and also described in the present report in the NBS
patient. The proliferative response of peripheral blood lymphocytes in
vitro to mitogens is deficient in NBS patients, but the possible link
among NBS mutations and the abnormal immune response is still unknown.
 |
INTRODUCTION |
Nijmegen breakage syndrome (NBS) is
a rare, autosomal recessive disorder characterized by microcephaly,
immunodeficiency, and a predisposition to cancer (27). It
shares some striking clinical and cellular similarities to the genetic
disease ataxia telangiectasia (AT), and for this reason, NBS has been
classified as a variant of AT (12). However, NBS patients
have neither ataxia nor telangiectasia, and microcephaly is absent from
AT patients (25, 27). The serum
-fetoprotein
concentration is within the normal range in NBS patients, in contrast
to AT patients, about 90% of whom are found to have elevated serum
-fetoprotein concentrations (31). In addition,
different defective genes in patients with AT and NBS have been
identified (3, 23, 28) and have been mapped in chromosomes
11q23 (8) and 8q21-24, respectively (22),
which demonstrates that NBS is a genetic entity distinct from AT.
Patients with both NBS and AT display chromosome instability,
hypersensitivity to ionizing radiation, and a lack of DNA replication delay in response to radiation, which is governed, in normal cells, by
the protein kinase C (PKC)-mediated upregulation of tumor suppresor protein p53 (9, 13, 14, 15, 18). These similarities suggest that ATM and nibrin, the proteins responsible for AT and NBS,
respectively, may play a role in common functions, which appear to be
defective in both diseases.
Both ATM and nibrin participate in the processing of double-stranded
breaks in DNA (3, 25). It has recently been shown that
nibrin, in particular, forms a trimolecular complex, together with
Rad50 (a protein similar to those required for the structural maintenance of chromosomes) and Mre11 (with both structural and catalytic activities, including single-stranded DNA endonuclease and
double-stranded DNA exonuclease activities). The complex participates in the repair of double-stranded DNA breaks induced by radiation, and
the Mre11 hyperphosphorylation observed after DNA damage is dependent
on the presence of intact nibrin (6, 7). Recently, it has
been shown that the phosphorylation of nibrin induced by ionizing
radiation requires catalytically active ATM (29, 32, 33),
demonstrating that both proteins may participate in common cellular
activation pathways.
The immune deficiency is also severe in patients with NBS and concerns
the humoral and cellular immune systems. Given the similarities between
NBS and AT, an extensive analysis of the immune system was carried out
in an NBS patient. Cellular, humoral, and innate immunities were
studied by determining variations in lymphocyte subpopulations,
peripheral blood mononuclear cell (PBMC) responses to a complete panel
of mitogens that analyze the different lymphocyte activation pathways
(T-cell function, B-cell function, and T- and B-cell cooperation),
immunoglobulin values, and circulating levels of complement. In
addition, the molecular characterization of our NBS patient's mutation
has also been carried out.
 |
MATERIALS AND METHODS |
Patient.
Our patient is a 5-year-old Spanish boy (born in
July 1995) from nonconsanguineous parents. The patient has
microcephaly, "bird-like" facies, short height, and normal levels
of
-fetoprotein. A brother, probably falsely diagnosed as having
lymphoma with Bloom syndrome, died after a bone marrow transplantation.
The patient's immunity was monitored for 3 years. He showed persistent fever and symptoms compatible with an acute Epstein-Barr virus (EBV)
infection; anti-EBV immunoglobulins (anti-VCA-immunoglobulin G [IgG],
141 [normal value, <11]; anti-VCA-IgM; 25 [normal value, <11];
anti-EBNA, 12 [normal value <11]) were detected in July 1998. Two
monoclonal IgM kappa paraproteins were also detected by
immunofixation-electrophoresis, and B-cell lymphocytosis was observed
in the periphery (see Table 1).
Immunochemistry and biochemical assays.
Total serum
immunoglobulin (IgG, IgA, and IgM) levels, complement factor (C3 and
C4) levels, and
-fetoprotein concentrations were measured by
nephelometry (Array 360 system; Beckman, Brea, Calif.). Serum hemolytic
capacity (CH100) and serum IgE, IgD, and IgG subclass levels were
measured with radial immunodiffusion kits (The Binding Site,
Birmingham, United Kingdom) and commercial reagents.
Proliferation assays with PBMCs.
A total of 8 × 104 PBMCs were placed in round-bottom microtiter plates
(Nunc, Roskilde, Denmark) in 170 µl of AIM-V culture medium (Gibco
BRL, Paisley, United Kingdom) supplemented with 1%
penicillin-streptomycin (Difco) and 1% glutamine (20 mM; Whittaker, Walkersville, Md.) (1). The optimal concentrations of each stimulus were calculated from the dose-response curves used in our
laboratory after standardization with control samples. The stimuli or
their combinations were used in triplicate, and the results were taken
into account if data were altered in several follow-up tests (see Table
2) (1). The wells were individually pulsed with 1 µCi of
[3H]thymidine after 3 days of culture, and uptake of the
[3H]thymidine was measured in a liquid scintillation
counter (1205-Betaplate; Pharmacia LKB-Wallac, Turku, Finland). To
facilitate the interpretation of the results, the data were normalized
as the net percentage of the counts per minute obtained with a given
stimulus relative to the maximum stimulus in the same assay (the
maximum stimulus or 100% response is equal to the stimulus obtained
with phytohemagglutinin A [PHA] plus interleukin-2 [IL-2], done in
parallel for each experiment): (the proliferative response to one
mitogen [in counts per minute] × 100)/maximum stimulus in the same
assay (in counts per minute). The counts per minute corresponding to
background proliferation (calculated with cells in AIM-V medium) were
always 0 to 1% of the mean counts per minute for all the stimuli for
the controls and the patient.
Cytogenetic studies.
Chromosome preparations and
Giemsa-stained metaphases were obtained by standard methods from
PHA-stimulated PBMCs (24). Chromosome instability, with
16% of peripheral cells showing spontaneous chromosome breaks, was
observed in the patient at the age of 1 year. The following
rearrangements were found: 5% t(7;14)(p13;q11.2); 1%
47,XY,der(7)t(7;14)
(p13;q11.2),der(7)t(7;7)(pter
q35::p13
pter),del(14)(q11.2),+f;4% inv(7)(p13;q35); 1% t(1;8)(p13;q24.1),inv(7)(p13q35);
3% t(7;14)(q35;q11.2); 1% t(1;7)(p13;q35); and 1%
t(14;20)(q11.2;q13.3). Analysis of 25 unbanded, stained metaphase cells
from PHA-stimulated PBMCs showed a spontaneous chromosome breakage rate
of 0.08 breaks/cell (control range, 0 to 0.05 breaks/cell), and
analysis of 50 unbanded, stained metaphase cells exposed to
diepoxybutane (0.1 µg/ml) showed a chromosome breakage rate of 0.26 breaks/cell (control range, 0 to 0.1 breaks/cell).
Cytofluorographic analysis.
For direct immunofluorescence,
105 cells were incubated for 30 min with monoclonal
antibodies for detection of the different lymphocyte populations (T, B,
and NK cells) and subpopulations (see Table 1) (1). Cells
were washed twice with phosphate-buffered saline plus 0.01%
NaN3, and three-color and quantitative analysis for
two-color fluorescence was carried out in an EPICS-XL flow cytometer
(20).
Scanning for mutations.
Cytoplasmic RNA was extracted by
using the Nonidet P-40 lysis method (24). DNA was obtained
from the nuclear pellet by standard methods (4). Reverse
transcription was done with 0.5 µg of cytoplasmic RNA by a one-step
reverse transcription-PCR method (Gibco BRL) by using for the reaction
specific, partly overlapping primers that cover all of the
nibrin-coding sequence. The primers used were NBS[1] (a)
(5'-AGCCCCGGTTACGCGGTTGC-3') and (b)
(5'-GGCTTTACAATTGGACGTCC-3'), NBS[2] (a)
(5'-ATGCACTCACCTTGTCATGG-3') and (b)
5'-CGCCAATCCAATTTCTGC-3'), NBS[3] (a)
5'-AATGGATATGCTCCAAAGGC-3') and (b)
(5'-TTATACTTGGCAATTTAGTTGG-3'), NBS[4] (a)
(5'-TTTGGCTAAGATGAGAATCC-3') and (b)
(5'-TTGCTACTTTCTGGTACTGC-3'), and NBS[5] (a)
(5'-AAGGCCAAGGATGGATATAG-3') and (b)
(5'-GCTTACTAGGAAGTTTTTCCATGG-3'). Additional primers used
for sequencing of the mutation in exon 6 were NBS(EX6D)
(5'-CACTCCGTTTACAATTTAATAGC-3') and NBS(EX6I) (5'-CACAAAATCCCAAAATGAAATACG-3'), which rendered a product
of 293 bp. DNA amplification was done as described previously
(4). Scanning for mutations was done by restriction
endonuclease fingerprinting assay (16). One microgram of
the PCR product was digested separately with five restriction
endonucleases. Denatured and nondenatured PCR digestion products were
electrophoresed in 6 to 10% polyacrylamide gels with the Protean II
vertical electrophoresis system (gel size; 20 by 20 cm; Bio-Rad
Laboratories, Hercules, Calif.) and silver stained (Bio-Rad). The
heteroduplex analysis was developed to determine the carrier status of
the patient's family. Briefly, an aliquot of the genomic 293-bp PCR
fragment was heat denatured and then renaturalized and electrophoresed
in a nondenaturing polyacrylamide gel.
For DNA sequencing, PCR products were purified by using the QIAquick
PCR purification kit (QIAGEN, Hilden, Germany). Double-stranded DNA was
directly sequenced by Sanger's dideoxy chain terminator method
(2) with dye-labeled dideoxy terminators by PCR (Applied Biosystems, Warrington, United Kingdom).
 |
RESULTS |
Mutation analysis and karyotype.
Nibrin cDNA was scanned for
mutations; the analysis was based on reverse transcription-PCR followed
by a modification of the restriction endonuclease fingerprinting assay
(16). The coding sequence of the nibrin mRNA was divided
into five partially overlapping fragments, and each fragment was
analyzed separately. The analysis showed a change in the NBS[3] cDNA
fragment with respect to that for a healthy control. Direct sequencing
revealed a homozygous 5-bp deletion (AAAAC) at nucleotide 657 (exon 6),
which shifts the normal reading frame from residue 238 and which
produces a truncation of the protein at residue 254 due to generation
of a premature stop codon, therefore, the normal nibrin protein is not
synthesized, causing the complete loss of function of this protein.
A heteroduplex assay of exon 6 was designed to test the carrier status
of the patient's parents. Figure 1 shows
a band of 293 bp corresponding to the nonmutated NBS gene fragment for
the normal control. For the lanes for the patient's father and mother, this band was indistinguishable from the one representing the mutated
allele, since the latter one is only 5 bp smaller. However, the lanes
for the parents showed two more bands which did not appear in those for
the control or the patient. In order to demonstrate that the two bands
could correspond to heteroduplexes formed among PCR products coming
from both mutated and nonmutated alleles, individual PCR products from
the control and the patient were mixed, heat denatured, renatured
again, and run in the electrophoresis (lane C+P). Figure 1 (lane C+P)
shows a two-band pattern similar to that described above, supporting
the presence of the heteroduplexes in the parents. This demonstrated
the carrier status of both parents for the same mutation.

View larger version (73K):
[in this window]
[in a new window]
|
FIG. 1.
Heteroduplex assay for the patient's family. Lanes: C,
control; F, father; P, patient; M, mother. In lane C+P, parts of the
control and patient amplifications were mixed and treated in the same
way. As can be seen, a heteroduplex is formed, as in the mutation
carriers. The homoduplex migrates at 293 bp in the control.
|
|
Karyotype analysis of the patient's PBMCs showed three different
clonal populations of cells (16% of the cells examined) with rearrangements involving chromosomes 7 and 14 at breakpoints 7p13, 7q35, and 14q11.2. The rearrangements corresponded to chromosome bands
containing immunologically relevant genes (T-cell-receptor
,
,
and
chains and the immunoglobulin heavy chain) (19).
Humoral immunity and lymphocyte subpopulations.
Humoral
immunity was altered in the patient: a total absence of IgG2, low IgG1
and IgG3 levels, and a severe IgG reduction were the main findings
(Table 1). The cellular peripheral
phenotype (Table 1) and the lymphocyte function (Table
2) were also dramatically altered. The
patient showed a progressive impairment in T-cell development, as shown
by the small number of CD3+ cells. Low CD4+
cell levels accounted for the CD3+-cell reduction, while
the CD8+ T-cell number was normal (Table 1). The patient
had a severe disruption of the CD4+ naive
cell/CD4+ memory cell ratio, with there being "memory"
cells almost exclusively (contrary to what is expected in a healthy
boy). A B-cell (CD19+) increase was recorded in the third
study, which, together with a biclonal IgM kappa paraprotein detection,
reflected the EBV infection recorded in the patient by that time. In
addition, a significant NK-cell (CD16+) increase was
recorded in the first two studies; the NK-cell number was normal in
August 1998 (Table 1). The following parameters analyzed were unaltered
in the patient compared to those for the controls:
C3, C4, and CH100
concentrations or activity in peripheral blood and
CD18, CD7, CD43,
CD57, T-cell receptor 
, and CD14 PBMC subpopulations (data not
shown).
Impairment of PMA plus lectin activating responses.
NBS
deficiency disrupts several lymphocyte activation pathways. The
patient's PBMCs presented decreased proliferative responses to some of
the stimuli assayed in the in vitro functional evaluation. The
normalization of the data and the use of a serum-free medium allowed
comparison of results obtained at different times (in long-term
follow-ups) (Table 2). The patient's proliferative responses to IL-2,
protein A, CD2, CD28, PHA, or CD3 alone were within the normal range of
values. The levels of enterotoxin A-, concanavalin A (ConA)-, and
pokeweed (PWM)-induced proliferation were reduced in two studies.
Moreover, when phorbol myristate acetate (PMA) was used as a costimulus
together with lectins (PHA [first study], ConA, and PWM) no
additional induction or a mild inhibition of the responses was
obtained. The following parameters were analyzed (using PKC- and
non-PKC-dependent stimuli) and were found to be unaltered in the
patient compared to those in the controls: proliferation mediated by
PMA, recombinant IL-2 (rIL-2), enterotoxin C1,
-CD2,
-CD2 plus
rIL-2,
-CD3 plus rIL-2,
-CD2 plus
-CD28,
-CD3 plus
-CD28, PHA plus rIL-2, ConA plus rIL-2, and ionomycin plus PMA (data
not shown). Also, a set of recall antigens produced no reaction in vivo
(30). Similar results were obtained for three different
patients with AT (6a).
 |
DISCUSSION |
The present work describes a genetic, phenotypic, and functional
characterization of a Spanish NBS patient. The 5-bp deletion in exon 6 has been described previously and represents the founder mutation in
most populations of NBS patients; this deletion is present in 90% of
the patients with NBS (11, 28). The alterations in
chromosomes 7 and 14 recorded in the patient are also commonly found in
patients with NBS (27). The chromosome alterations affect
the T-cell receptor
-,
-, and
-chain genes. This could explain
the rearrangement failures in T-cell receptors, the probable accumulation of unstable hybrid T-cell receptor molecules and the
abortion of its surface expression, and the small number of CD3+ cells. A low proportion of the CD4+ T-cell
subset and a decreased CD4+/CD8+ ratio were
also found. The prevalence of memory CD4+ cells (and the
practical absence of naive CD4+ cells) is described in
patients with NBS. Thus, it is possible that a reduced output of T
cells from the thymus leads to the accumulation of memory T cells in
the periphery. This also occurs in AT patients, in whom dysplastic
changes or the absence of the thymus is constantly found
(19). The reasons for the large numbers of NK cells
observed throughout the first set of studies (Table 1) remain unknown,
but a relatively large number of NK cells was noted in other NBS
patients (5). On the other hand, the IgG2 deficiency has
also been observed in patients with other primary immunodeficiencies
that affect T-cell receptor expression and/or function, like those with
the CD3
deficiency (21).
B-cell function was deregulated in the patient and protein A (B-cell
antigen)-induced responses were normal in the patient only in the first
study, with the deregulation confirmed by the observed reduction in IgG
levels in the periphery. Moreover, T-cell-B-cell cooperation, as
measured by PWM-induced mitogenesis (which acts by contact of T cells
and B cells) was also affected. Naive T cells (CD4+
CD45RA+) are supposed to proliferate better with classical
mitogens (PHA, ConA, PWM), and these response patterns (low-level
proliferative responses to PHA, Con A and PWM) strongly correlate with
the very low proportion of CD4+ CD45RA+ T cells
in the patient (19).
The immune consequences of a deficiency of the NBS gene product in many
ways resemble the abnormalities seen in AT: hypogammaglobulinemia, alteration of the proportions of lymphocyte subpopulations, and similar
defective blastogeneses.
The results obtained from the functional assays with PBMCs show an
impairment in some of the lymphocyte proliferative responses induced by
PMA, which is an analogue of diacylglycerol and a specific direct
activator of the PKC pathway. We have previously reported that PBMCs
from AT patients show a general impaired response to different
mitogens, especially when phorbol esters (like PMA) are used as
costimuli. In patients with AT, PMA inhibits in particular T-lymphocyte
proliferative responses to CD3, CD28, and PHA, as well as, mainly, to
ConA, PWM, anti-CD26, and anti-CD69.
Interestingly, some evidence for an interplay of the NBS gene product
with the ATM protein has been derived from complementation studies
based on radiation-induced chromosome breakage in heterodikaryons made
from cells from patients with NBS and AT (26, 29, 31, 32).
The data obtained from AT patients suggest a differential dependence of
PKC isoforms (10) in differential transduction pathways.
Moreover, as in AT, the protein coded by the NBS gene, nibrin, may also
be involved in cell cycle control, with nibrin acting on p53 modulating
genome stability, tumor susceptibility, and apoptosis
(17).
Finally, further biochemical assays are needed to find out whether
there is more than one PKC activation pathway.
 |
ACKNOWLEDGMENTS |
The contributions of M. A. García-Pérez and
L. M. Allende were equal, and the order of the authors is arbitrary.
This work was supported in part by grants from the Ministerio de
Educación y Ciencia (PM95-57, PM96-21, and PM99-23) and Comunidad
de Madrid (06/70/97 and 83/14/98).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Immunology, Hospital 12 de Octubre, Carretera de Andalucia,
28041-Madrid, Spain. Phone: 34-91-3908315. Fax: 34-91-3908399. E-mail:
aarnaiz{at}eucmax.sim.ucm.es.
 |
REFERENCES |
| 1.
|
Allende, L. M.,
A. Corell,
J. Manzanares,
D. Madruga,
A. Marcos,
A. Madroño,
A. López-Goyanes,
M. A. García-Pérez,
J. M. Moreno,
M. Rodrigo,
F. Sanz, and A. Arnaiz-Villena.
1998.
Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding.
Immunology
94:543-551[CrossRef][Medline].
|
| 2.
|
Arnaiz-Villena, A.,
M. Timón,
A. Corell,
P. Pérez-Aciego,
J. M. Martín-Villa, and J. R. Regueiro.
1992.
Primary immunodeficiency caused by mutations in the gene encoding the CD3- subunit of the T-lymphocyte receptor.
N. Engl. J. Med.
327:529-533[Medline].
|
| 3.
|
Carney, J. P.,
R. S. Maser,
H. Olivares,
E. M. Davis,
M. Le Beau,
J. R. Yates,
L. Hays,
W. F. Morgan, and J. H. Petrini.
1998.
The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response.
Cell
93:477-486[CrossRef][Medline].
|
| 4.
|
Corell, A.,
J. M. Martin-Villa,
P. Morales,
M. D. de Juan,
P. Varela,
J. L. Vicario,
J. Martínez-Laso, and A. Arnaiz-Villena.
1991.
Exon-2 nucleotide sequences, polymorphism and haplotype distribution of a new HLA-DRB gene: HLA-DRB .
Mol. Immunol.
28:533-543[CrossRef][Medline].
|
| 5.
|
Der Kaloustian, V. M.,
W. Kleijer,
A. Booth,
A. D. Auerbach,
B. Mazer,
A. M. Elliott,
S. Abish,
R. Usher,
G. Watters,
M. Vekemans, and P. Eydoux.
1996.
Possible new variants of the Nijmegen breakage syndrome.
Am. J. Hum. Genet.
65:21-26.
|
| 6.
|
Dong, Z.,
Q. Zhong, and P. L. Chen.
1999.
The Nijmegen breakage syndrome protein is essential for Mre11 phosphorylation uponDNA damage.
J. Biol. Chem.
274:19153-19156.
|
| 6a.
|
García-Pérez, M. A.,
L. M. Allende,
A. Corell,
P. Varela,
A. A. Moreno,
A. Sotoca,
A. Moreno,
E. Paz-Artal,
E. Barreiro, and A. Arnaiz-Villena.
2001.
Novel mutations and defective protein kinase C activation of T-lymphocytes in ataxia-telangiectasia.
Clin. Exp. Immunol.
123:472-480[CrossRef][Medline].
|
| 7.
|
Gatei, M.,
D. Young,
K. M. Cerosaletti,
A. Desai-Mehta,
K. Spring,
S. Kozlov,
M. F. Lavin,
R. A. Gatti,
P. Concannon, and K. Khanna.
2000.
ATM-dependent phosphorylation of nibrin in response to radiation exposure.
Nat. Genet.
25:115-119[CrossRef][Medline].
|
| 8.
|
Gatti, R. A.,
I. Berkel,
E. Boder,
G. Braedt,
P. Charmley,
P. Concannon,
F. Ersoy,
T. Foround,
N. G. Jaspers,
K. Lange, et al.
1988.
Localization of an ataxia-telangiectasia gene to chromosome 11q22-23.
Nature
336:577-580[CrossRef][Medline].
|
| 9.
|
Gennery, A. R.,
A. J. Cant, and P. A. Jeggo.
2000.
Immunodeficiency associated with DNA repair defects.
Clin. Exp. Immunol.
121:1-7[CrossRef][Medline].
|
| 10.
|
Hofmann, J.
1997.
The potential for isoenzyme-selective modulation of protein kinase C.
FASEB J.
11:649-669[Abstract].
|
| 11.
|
The International Nijmegen Syndrome Study Group.
2000.
Nijmegen breakage syndrome.
Arch. Dis. Child.
82:400-406[Abstract/Free Full Text].
|
| 12.
|
Jaspers, N. G.,
R. D. Taalman, and C. Baan.
1988.
Patients with an inherited syndrome characterized by immunodeficiency, microcephaly, and chromosomal instabilty; genetic relationship to ataxia-telangiectasia.
Am. J. Hum. Genet.
42:66-73[Medline].
|
| 13.
|
Jongmans, W.,
M. Vuillaume,
K. Chrzarowska,
D. Smeets,
K. Sperling, and J. Hall.
1997.
Nijmegen breakage syndrome cells fail to induce the p53-mediated DNA damage response following exposure to ionizing radiation.
Mol. Cell. Biol.
17:5016-5022[Abstract].
|
| 14.
|
Kastan, M. B.,
Q. Zhan,
W. S. el-Deiry,
F. Carrier,
T. Jacks,
W. V. Walsh,
B. S. Plunkett,
B. Vogelstein, and A. J. Fornace, Jr.
1992.
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.
Cell
71:587-597[CrossRef][Medline].
|
| 15.
|
Khanna, K. K., and M. F. Lavin.
1993.
Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells.
Oncogene
8:3307-3312[Medline].
|
| 16.
|
Liu, Q., and S. S. Sommen.
1995.
Restriction endonuclease fingerprinting (REF): a sensitive method for screening mutations in long, contiguous segments of DNA.
BioTechniques
18:470-477[Medline].
|
| 17.
|
Meyn, M. S.
1995.
Ataxia-telangiectasia and cellular responses to DNA damage.
Cancer Res.
55:5991-6001[Abstract/Free Full Text].
|
| 18.
|
Mirzayans, R.,
K. S. Famulski,
L. Enns,
M. Fraser, and M. C. Paterson.
1995.
Characterization of the signal transduction pathway mediating gamma ray-induced inhibition of DNA synthesis in human cells: indirect evidence for involvement of calmodulin but not protein kinase C nor p53.
Oncogene
11:1597-1605[Medline].
|
| 19.
|
Paganelli, R.,
E. Scala,
E. Scarselli,
C. Ortolani,
A. Cossarizza,
D. Carmini,
F. Aiuti, and M. Fiorilli.
1992.
Selective deficiency of CD4+/CD45RA+ lymphocytes in patients with ataxia-telangiectasia.
J. Clin. Immunol.
12:84-91[CrossRef][Medline].
|
| 20.
|
Pérez-Aciego, P.,
B. Alarcón,
A. Arnaiz-Villena,
C. Terhorst,
M. Timon,
O. G. Segurado, and J. R. Regueiro.
1991.
Expression and function of a variant T cell receptor complex lacking CD3- .
J. Exp. Med.
174:319-326[Abstract/Free Full Text].
|
| 21.
|
Regueiro, J. R.,
P. Pérez-Aciego,
P. Aparicio,
C. Martínez,
P. Morales, and A. Arnaiz-Villena.
1990.
Low IgG2 and polysaccharide response in a T cell receptor expression defect.
Eur. J. Immunol.
20:2411-2416[Medline].
|
| 22.
|
Saar, K.,
K. H. Chrzanowska,
M. Stumm,
M. Jung,
G. Nurnberg,
T. F. Wienker,
E. Seemanova,
R. D. Wegner,
A. Reis, and K. Sperling.
1997.
The gene for the ataxia-telangiectasia variant, Nijmegen breakage syndrome, maps to a 1 cM interval on chromosome 8q21.
Am. J. Hum. Genet.
60:605-610[Medline].
|
| 23.
|
Savitsky, K.,
A. Bar-Shira,
S. Gilad,
G. Rotman,
Y. Ziv,
L. Vanagaite,
D. A. Tagle,
S. Smith,
T. Uziel,
S. Sfez, et al.
1995.
A single ataxia telangiectasia gene with a product similar to PI-3 Kinase.
Science
268:1749-1753[Abstract/Free Full Text].
|
| 24.
|
Seabright, M. A.
1997.
A rapid banding technique for human cytogenetics.
Lancet
ii:971-972.
|
| 25.
|
Shiloh, Y.
1997.
Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart.
Annu. Rev. Genet.
31:635-662[CrossRef][Medline].
|
| 26.
|
Stumm, M.,
K. Sperling, and R. D. Wegner.
1997.
Noncomplementation of radiation-induced chromosome aberrations in ataxia-telangiectasia/ataxia-telangiectasia-variant heterodikaryons.
Am. J. Hum. Genet.
60:1246-1251[CrossRef][Medline].
|
| 27.
|
van der Burgt, I.,
K. H. Chrzanowska,
D. Smeets, and C. Weemaes.
1996.
Nijmegen breakage syndrome.
J. Med. Genet.
33:153-156[Abstract].
|
| 28.
|
Varon, R.,
C. Vissinga,
M. Platzer,
K. M. Cerosaletti,
K. H. Chrzanowska,
K. Saar,
G. Beckmann,
E. Seemanova,
P. R. Cooper,
N. J. Nowak,
M. Stumm,
C. M. Weemaes,
R. A. Gatti,
R. K. Wilson,
M. Digweed,
A. Rosenthal,
K. Sperling,
P. Cancannon, and A. Reis.
1998.
Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome.
Cell
93:467-476[CrossRef][Medline].
|
| 29.
|
Wang, J. Y. J.
2000.
New link via a web of human genes.
Nature
405:404-405[CrossRef][Medline].
|
| 30.
|
Wegner, R. D.,
M. Metzger,
F. Hanefeld,
N. G. J. Jaspers,
C. Baan,
K. Magdorf,
J. Kunze, and K. Sperling.
1988.
A new chromosomal instability disorder confirmed by complementation studies.
Clin. Genet.
33:20-32[Medline].
|
| 31.
|
Woods, C. G., and A. M. R. Taylor.
1992.
Ataxia-telangiectasia in the British Isles. The clinical and laboratory features of 70 affected individuals.
Q. J. Med. New Ser.
82:169-179.
|
| 32.
|
Wu, X.,
V. Ranganathan,
D. S. Weisman,
W. F. Heine,
D. N. Ciccone,
T. B. O'Neill,
K. E. Crick,
K. A. Pierce,
W. S. Lane,
G. Rathbun,
D. M. Livingston, and D. T. Weaver.
2000.
ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response.
Nature
405:477-482[CrossRef][Medline].
|
| 33.
|
Zhao, S.,
Y. C. Weng,
S. S. Yuan,
Y. T. Lin,
H. C. Hsu,
S. C. Lin,
E. Gerbino,
M. H. Song,
M. Z. Zdzienicka,
R. A. Gatti,
J. W. Shay,
Y. Ziv,
Y. Shiloh, and E. Y. Lee.
2000.
Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products.
Nature
405:473-477[CrossRef][Medline].
|
Clinical and Diagnostic Laboratory Immunology, July 2001, p. 757-761, Vol. 8, No. 4
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.4.757-761.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.